106331-71-9

Basic information

• Product Name: 2,3-dibromo-5,6-dimethoxypyridine
• Synonyms: 2,3-dibromo-5,6-dimethoxypyridine
• CAS NO: 106331-71-9
• Molecular Formula: C₇H₇Br₂NO₂
• Molecular Weight: 296.94398
• Mol File: 106331-71-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,3-dibromo-5,6-dimethoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dibromo-5,6-dimethoxypyridine(106331-71-9)
• EPA Substance Registry System: 2,3-dibromo-5,6-dimethoxypyridine(106331-71-9)

Safety Data

• Hazardous Substances Data: 106331-71-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2,3-dibromo-5,6-dimethoxypyridine is used as a reagent in various organic reactions, such as Suzuki-Miyaura cross-coupling and Sonogashira coupling reactions. Its presence in these reactions facilitates the formation of new carbon-carbon and carbon-heteroatom bonds, contributing to the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,3-dibromo-5,6-dimethoxypyridine serves as an intermediate in the synthesis of potential drug candidates. Its unique structure and functional groups make it a valuable building block for the development of new therapeutic agents.
Used in Medicinal Chemistry:
2,3-dibromo-5,6-dimethoxypyridine is utilized in medicinal chemistry for the preparation of bioactive compounds. Its structural features allow for the design and synthesis of molecules with potential therapeutic properties, contributing to the discovery of new drugs.
Used in Material Science:
2,3-dibromo-5,6-dimethoxypyridine also finds applications in material science, where it can be incorporated into the development of novel materials with specific properties. Its versatility and reactivity make it a promising candidate for creating advanced materials with applications in various fields.

Upstream product

• 52605-96-6 2-chloro-3-methoxypyridine 
• 6636-78-8 2-chloro-3-hydroxypyridine 
• 52605-97-7 2,3-dimethoxypyridine 

Downstream Products

• 1333147-33-3 2-(biphenyl-3-yl)-5,6-dimethoxypyridine-3-carbonitrile 
• 1333146-70-5 2-(biphenyl-3-yl)-5-hydroxy-6-oxo-1,6-dihydropyridine-3-carbonitrile 
• 1333147-39-9 3-(biphenyl-3-yl)-5,6-dimethoxypyridine-2-carbonitrile 
• 1333146-72-7 3-(biphenyl-3-yl)-5-hydroxy-6-oxo-1,6-dihydropyridine-2-carbonitrile 
• 106331-72-0 5-bromo-2,3,6-trimethoxypyridine 
• 1581767-43-2 2,3-dimethoxy-5,6-bis(3-carbamoylphenyl)pyridine 
• 1581767-42-1 2,3-dimethoxy-5,6-bis(4-carbamoylphenyl)pyridine 
• 1581767-41-0 2,3-dimethoxy-5,6-bis(4-nitrophenyl)pyridine 
• 1581767-02-3 5-hydroxy-3,3'-(6-oxo-1,6-dihydropyridine-2,3-diyl)dibenzamide 
• 1581767-01-2 5-hydroxy-4,4'-(6-oxo-1,6-dihydropyridine-2,3-diyl)dibenzamide 
• 1581767-00-1 3-hydroxy-5,6-bis(4-nitrophenyl)pyridin-2(1H)-one 
• 1581766-99-5 5,6-bis(3-fluorophenyl)-3-hydroxypyridin-2(1H)-one 
• 1581767-27-2 C₂₄H₁₈FNO₂ 
• 1581767-68-1 4-((2-(4-fluorophenyl)-5,6-dimethoxypyridin-3-yl)amino)benzonitrile 

Relevant articles and documents

Aryl and Arylalkyl Substituted 3-Hydroxypyridin-2(1H)-ones: Synthesis and Evaluation as Inhibitors of Influenza A Endonuclease

Seasonal influenza infections are associated with an estimated 250–500 000 deaths annually. Resistance to the antiviral M2 ion-channel inhibitors has largely invalidated their clinical utility. Resistance to neuraminidase inhibitors has also been observed in several influenza A virus (IAV) strains. These data have prompted research on inhibitors that target the cap-snatching endonuclease activity of the polymerase acidic protein (PA). Baloxavir marboxil (Xofluza), recently approved for clinical use, inhibits cap-snatching endonuclease. Resistance to Xofluza has been reported in both in vitro systems and in the clinic. An X-ray crystallographic screening campaign of a fragment library targeting IAV endonuclease identified 5-chloro-3-hydroxypyridin-2(1H)-one as a bimetal chelating agent at the active site. We have reported the structure–activity relationships for 3-hydroxypyridin-2(1H)-ones and 3-hydroxyquinolin-2(1H)-ones as endonuclease inhibitors. These studies identified two distinct binding modes associated with inhibition of this enzyme that are influenced by the presence of substituents at the 5- and 6-positions of 3-hydroxypyridin-2(1H)-ones. Herein we report the structure–activity relationships associated with various para-substituted 5-phenyl derivatives of 6-(p-fluorophenyl)-3-hydroxypyridin-2(1H)-ones and the effect of using naphthyl, benzyl, and naphthylmethyl groups as alternatives to the p-fluorophenyl substituent on their activity as endonuclease inhibitors.

PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR

The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Synthetic method of 2,5,6-trimethoxy-3-picolinic acid

The invention relates to a synthetic method of 2,5,6-trimethoxy-3-picolinic acid, which mainly solves the technical problem that no effective synthetic methods are provided at present. The synthetic method provided by the invention comprises the following steps: converting 2-chloro-3-hydroxypyridine hydroxy into methoxy; carrying out methoxy nucleophilic substitution of chlorine; carrying out bromination of a pyridine ring; and carrying out methoxy selective substitution of bromine; removing bromine from n-butyllithium, reacting with carbon dioxide, and introducing carboxy so as to obtain 2,5,6-trimethoxy-3-picolinic acid. In the whole synthetic process, intermediates and object products do not need to be separated through a chromatographic column, the raw materials are cheap, and the purification is simple.

PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR

The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES

The invention provides compounds of formula (I): and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Phenyl substituted 3-hydroxypyridin-2(1H)-ones: Inhibitors of influenza A endonuclease

Inhibition of the endonuclease activity of influenza RNA-dependent RNA polymerase is recognized as an attractive target for the development of new agents for the treatment of influenza infection. Our earlier study employing small molecule fragment screening using a high-resolution crystal form of pandemic 2009 H1N1 influenza A endonuclease domain (PAN) resulted in the identification of 5-chloro-3-hydroxypyridin-2(1H)-one as a bimetal chelating ligand at the active site of the enzyme. In the present study, several phenyl substituted 3-hydroxypyridin-2(1H)-one compounds were synthesized and evaluated for their ability to inhibit the endonuclease activity as measured by a high-throughput fluorescence assay. Two of the more potent compounds in this series, 16 and 18, had IC50 values of 11 and 23 nM in the enzymatic assay, respectively. Crystal structures revealed that these compounds had distinct binding modes that chelate the two active site metal ions (M1 and M2) using only two chelating groups. The SAR and the binding mode of these 3-hydroxypyridin-2-ones provide a basis for developing a new class of anti-influenza drugs.

INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS

The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. Th

New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists

Compounds of formula: are disclosed wherein R and R1 are (a) hydrogen;(b) haloloweralkyl;(c) halo;(d) CONR2R3 wherein R2 and R3 independently represent hydrogen, C1-8 alkyl, or C3-8 cycloalkyl;(e) loweralkenyl;(f)-COR2;(g)-CH?OR2;(h) loweralkynyl;(i)-CH?NR2R3;(j)-CH?SR2;(k) =O; or(l)-OR2;(m)-R2; Ar and Ar1 are (a) phenyl or substituted phenyl of formula where R?-R? independently represent H; R2; YO-wherein Y is loweralkenyl, loweralkynyl,-CH? ,-CH?C(O) OR2,-CH?OR2,-CH?C3-8cycloalkyl,-CH? Ar2 wherein Ar2 is phenyl or substituted phenyl,-CH?-CH(OH)-CH? OH; R2S-(O)n wherein R2 can only be C3-8 cycloalkyl and n is 0 to 2; CF?SO, CF?SO?;-CONR2R3;-NR2COR3;-OCONH?-CR2R3R? wherein R? is the same as or different from R2;-CH?OR2;-CH?CO?R2;-CH?OCOR3;-CH?O-CO-OR2;-NHCH?COOR2; halo; or N?R2R3R?X? wherein X? is an anion;(b) monoheteroaryl, di-or polyheteroaryl or fused heteroaryl containing 1 to 3 of any one or more of the heteroatoms N, S or O;(c) heteroarylalkyl;(d) heterocycloalkyl; or(e) heterocycloalkenyl. These compounds are found to have potent and specific PAF (Platelet Activating Factor) antagonistic activities.